Sugi Predict

Sugi Predict / Targets / PSMB9

PSMB9

Proteasome subunit beta type-9 · P28065 · PSMB9 on Sugi Atlas →

32,024 patent compounds predicted against PSMB9, 20,731 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL605949 SCHEMBL605949 0.54 15/20
SCHEMBL607010 SCHEMBL607010 0.56 12/20
SCHEMBL609327 SCHEMBL609327 0.55 12/20
SCHEMBL607553 SCHEMBL607553 0.54 12/20
SCHEMBL464435 SCHEMBL464435 0.54 12/20
SCHEMBL606932 SCHEMBL606932 0.53 12/20
SCHEMBL608381 SCHEMBL608381 0.53 12/20
SCHEMBL609081 SCHEMBL609081 0.52 12/20
SCHEMBL606926 SCHEMBL606926 0.52 12/20
SCHEMBL606344 SCHEMBL606344 0.51 12/20
SCHEMBL606616 SCHEMBL606616 0.51 12/20
SCHEMBL234139 SCHEMBL234139 0.71 11/20
Leucine Leucine (SCHEMBL1041561) 0.63 11/20
SCHEMBL607035 SCHEMBL607035 0.61 11/20
SCHEMBL609733 SCHEMBL609733 0.60 11/20
SCHEMBL609324 SCHEMBL609324 0.60 11/20
SCHEMBL605158 SCHEMBL605158 0.59 11/20
SCHEMBL606315 SCHEMBL606315 0.59 11/20
SCHEMBL609290 SCHEMBL609290 0.57 11/20
SCHEMBL464494 SCHEMBL464494 0.56 11/20

Clinical trials — most relevant to PSMB9 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease PHASE4UNKNOWN
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer PHASE2COMPLETED
MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma PHASE2WITHDRAWN
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors PHASE2COMPLETED
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma PHASE2COMPLETED
A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma PHASE2WITHDRAWN
The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy PHASE2NOT_YET_RECRUITING
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma PHASE2COMPLETED
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study PHASE2WITHDRAWN
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma PHASE1COMPLETED
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer PHASE1COMPLETED
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma PHASE1COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors PHASE1COMPLETED
A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma PHASE1COMPLETED
Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer PHASE1COMPLETED
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS nanCOMPLETED
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment nanUNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
The PREServation of MUScle Function in Critically Ill Patients (PRESMUS) nanUNKNOWN
Cardiovascular Complications of Carfilzomib Treatment nanUNKNOWN
Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT) nanUNKNOWN
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men nanRECRUITING
The Pathophysiology of Bortezomib Induced Peripheral Neuropathy nanUNKNOWN
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract nanUNKNOWN
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis nanUNKNOWN
Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia nanRECRUITING
Collection of Blood Samples for DNA in Motor Neuron Disease nanCOMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PSMB9 binder may also engage these)

ProteinNameSimilarity
Q3SZC2 — 1.000 Q3SZC2 →
O35521 — 1.000 O35521 →
O35524 — 1.000 O35524 →
O35523 — 1.000 O35523 →
P28077 — 1.000 P28077 →
P28076 — 1.000 P28076 →
O35522 — 1.000 O35522 →
Q3MHN0 — 0.999 Q3MHN0 →
PSMB6 Proteasome subunit beta type-6 0.994 landscape →
Q8UW64 — 0.994 Q8UW64 →
P28073 — 0.993 P28073 →
Q60692 — 0.992 Q60692 →
Q9DD33 — 0.992 Q9DD33 →
Q9PT26 — 0.990 Q9PT26 →
Q8LD27 — 0.989 Q8LD27 →
A7KE01 — 0.988 A7KE01 →
Q8SR11 — 0.987 Q8SR11 →
P38624 — 0.987 P38624 →
A7KII6 — 0.987 A7KII6 →
P93395 — 0.986 P93395 →
P28075 — 0.985 P28075 →
P28064 — 0.985 P28064 →
O55234 — 0.984 O55234 →
A1XQU1 — 0.984 A1XQU1 →
PSMB7 Proteasome subunit beta type-7 0.983 landscape →
PSMB5 Proteasome Macropain subunit MB1 0.983 landscape →
Q3T0T1 — 0.983 Q3T0T1 →
P28063 — 0.983 P28063 →
Q0J006 — 0.983 Q0J006 →
A2YXU2 — 0.982 A2YXU2 →